STOCK TITAN
  1. Home
  2. News
  3. STAA

Staar Surgical Co - STAA STOCK NEWS

Welcome to our dedicated page for Staar Surgical Co news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surgical Co stock.

Staar Surgical Co (NASDAQ: STAA) is a prominent player in the ophthalmic surgery market, with over three decades of experience. The company specializes in the development, manufacture, and marketing of implantable lenses and accompanying delivery systems for the eye. Staar Surgical's flagship product line includes the EVO Visian Implantable Collamer® Lenses (ICLs), which are used to treat a variety of visual disorders such as myopia, hyperopia, astigmatism, and presbyopia.

These lenses are designed to provide visual freedom to patients, significantly reducing or eliminating their reliance on glasses or contact lenses. The EVO Visian ICLs are foldable, allowing for a minimally invasive procedure where the lens is inserted through a small incision. This innovative approach not only enhances surgical outcomes but also minimizes recovery time for patients.

To date, nearly 600,000 EVO Visian ICLs have been implanted worldwide, showcasing the trust and effectiveness of Staar Surgical's products. Additionally, the company offers minimally invasive intraocular lenses (IOLs) geared towards cataract surgery. These include foldable IOLs and aspheric IOLs that deliver a clearer image compared to traditional spherical lenses.

Staar Surgical's commitment to advancing ophthalmic technology is evident in its continuous efforts to improve product offerings and expand its market reach. The company has formed strategic partnerships and collaborations to bolster its research and development initiatives, ensuring the delivery of cutting-edge solutions in eye care.

Financially, Staar Surgical has shown consistent growth, with the majority of its revenue generated from the ophthalmic surgical product segment. The company's focus remains on innovation and quality, driving its mission to enhance vision care globally.

News

STAAR Surgical to Report Fourth Quarter Results on February 26, 2024

Rhea-AI Summary
STAAR Surgical Company (NASDAQ: STAA) will release financial results for the fourth quarter ending December 29, 2023, on February 26, 2024. The company will host a conference call to discuss its financial results and operational progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News

STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision

Rhea-AI Summary
STAAR Surgical Company (NASDAQ: STAA) has announced a strategic agreement with SharpeVision to provide EVO ICL lenses as the first choice for patients seeking visual freedom from contact lenses and glasses. The collaboration includes marketing and education activities to increase awareness and availability of the lenses to all qualified patients in SharpeVision clinics. The initial stage of the collaboration includes a target purchase amount of 1,000 ICL units annually, which represents approximately 25% of the group’s refractive procedure volume. The EVO ICL lens can permanently correct vision without removing corneal tissue and is removable by a doctor for added peace of mind. The lens aims to eliminate the hassles of glasses and contact lenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.69%
Tags
none
-
News

STAAR Surgical Announces Preliminary Results for Fourth Quarter and Fiscal 2023

Rhea-AI Summary
STAAR Surgical Company (NASDAQ: STAA) reported a 19% increase in net sales for the fourth quarter and a 13% increase for fiscal 2023. The company also announced a sales outlook of $335 million to $340 million for fiscal 2024. Operating margin is expected to be approximately 5% for both the fourth quarter and fiscal 2023. Global ICL sales increased 22% in the fourth quarter and 18% for fiscal 2023, with a positive market share gain and continued profitability. The company's cash, cash equivalents, and investments available for sale also increased to approximately $230 million as of December 29, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.52%
Tags
earnings
News

Lilian Zhou Appointed to STAAR Surgical Board of Directors

Rhea-AI Summary
STAAR Surgical Company (NASDAQ: STAA) appoints Lilian Zhou, an accomplished investment portfolio manager, to its Board of Directors. Ms. Zhou brings over two decades of capital markets and investment experience to STAAR, having worked at highly regarded Wall Street investment institutions and founded her own firm. The company also announced the departure of Gil Kliman, M.D., from the board to focus on other commitments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.61%
Tags
management
-
News

STAAR Surgical to Present at Stephens Annual Investment Conference (NASH2023)

Rhea-AI Summary
STAAR Surgical Company (STAA) to Participate in Stephens Annual Investment Conference on November 16, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
conferences
-
News

STAAR Surgical Reports Third Quarter 2023 Results

Rhea-AI Summary
STAAR Surgical Company reported net sales of $80.3 million for the third quarter of 2023, a 6% increase compared to the prior year quarter. ICL sales were $81.1 million, up 13% year over year. Gross margin was 79.2%. Net income was $0.10 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.87%
Tags
earnings
News

STAAR Surgical to Report Third Quarter Results on November 1, 2023

Rhea-AI Summary
STAAR Surgical Company to release Q3 2023 financial results and host conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
conferences earnings
-
News

STAAR Surgical Celebrates 30th Anniversary of Implantable Collamer® Lens (ICL)

Rhea-AI Summary
STAAR Surgical Company celebrates the 30th anniversary of its Implantable Collamer Lens (ICL)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
none
-
News

Jimmy O. Yang Partners with STAAR Surgical to Shine a Light on Their Vision Correction Lens, EVO ICL

Rhea-AI Summary
STAAR Surgical announces partnership with Jimmy O. Yang for EVO ICL lenses
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
partnership
News

STAAR Surgical to Ring Nasdaq Stock Market Closing Bell Following Vision 2026 Investor Day on September 14, 2023

Rhea-AI Summary
STAAR Surgical Company holds Vision 2026 investor day and celebrates 40th anniversary of being listed as a public company
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
none

FAQ

What is the current stock price of Staar Surgical Co (STAA)?

The current stock price of Staar Surgical Co (STAA) is $24.82 as of December 20, 2024.

What is the market cap of Staar Surgical Co (STAA)?

The market cap of Staar Surgical Co (STAA) is approximately 1.2B.

What does Staar Surgical Co specialize in?

Staar Surgical Co specializes in developing, manufacturing, and marketing implantable lenses and delivery systems for ophthalmic surgeries.

What are EVO Visian Implantable Collamer Lenses (ICLs)?

EVO Visian ICLs are lenses used to treat visual disorders like myopia, hyperopia, astigmatism, and presbyopia, offering visual freedom by reducing reliance on glasses or contact lenses.

How many EVO Visian ICLs have been implanted to date?

Nearly 600,000 EVO Visian ICLs have been implanted worldwide.

What are the main types of products offered by Staar Surgical Co?

Staar Surgical Co offers two primary product types: Implantable Collamer Lenses (ICLs) for refractive surgery and intraocular lenses (IOLs) for cataract surgery.

What are the benefits of Staar Surgical's foldable lenses?

The foldable nature of Staar Surgical's lenses allows for minimally invasive procedures, enabling insertion through a small incision and reducing recovery time.

What financial segment contributes most to Staar Surgical's revenue?

The majority of Staar Surgical's revenue comes from the ophthalmic surgical product segment.

What innovations have Staar Surgical introduced in cataract surgery?

Staar Surgical offers minimally invasive intraocular lenses, including foldable IOLs and aspheric IOLs, which provide clearer images than traditional spherical lenses.

How does Staar Surgical ensure the quality of its products?

Staar Surgical focuses on continuous innovation, strategic partnerships, and rigorous research and development to maintain high-quality product offerings.

What are the core markets for Staar Surgical's products?

Staar Surgical's products primarily serve the refractive surgery market with its ICLs and the cataract surgery market with its IOLs.

What are some recent achievements of Staar Surgical?

Recent achievements include the global implantation of nearly 600,000 EVO Visian ICLs and advancements in minimally invasive cataract surgery lenses.

Stock STAA logo
Staar Surgical Co

Nasdaq:STAA

STAA Rankings

#2347 Ranked by Market Cap
N/A Ranked by Dividends

STAA Stock Data

1.24B
48.98M
0.53%
99.08%
5.75%
Medical Instruments & Supplies
Ophthalmic Goods
Link
United States of America
MONROVIA